Stefan Yee

chairman and non – executive director

Mr. Stefan Yee has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance.

Mr. Stefan Yee has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance, investment banking and private equity with companies as KPMG, Linklaters, the Flemish investment bank Lessius, the Belgian Corporation for International Investment (SBI/BMI), Beluga (Euronext Brussels) and as the founder and CEO of the PE Group, a Belgian privately held private equity firm. Stefan is, and has been an investor and/or board member of several listed and private companies such as, amongst others, Beluga, Encare group (Mensura), AXI, The Reference, Alro Holdings, Loomans Group, United Brands, Capco, Faseas International (Spacewell), HD Partners (Dekabo group), AED Rent, UnifiedPost Group, NRG New Generation, Axiles Bionics, including several healthcare companies (Docpharma (formerly Euronext Brussels), Uteron Pharma and Imcyse). Stefan holds Masters degrees in Law and Business Management from the Universities of Brussels (VUB and ULB Solvay Business School) and the University of Chicago (as a BAEF Fellow).

Leon Van Rompay

non – executive director

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in.

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in several positions including country & area manager (covering major territories) and board member of the Zambon Group. He was founder and CEO of Docpharma, a Belgian based generics company that was listed on Euronext and served on different boards including Ecodis and Uteron Pharmaceuticals. He was a founding member of BIGE/IBES (Belgian Institute for Health and Economics), the B.G.A. (Belgian Generic Association), BAPIE (Belgian Association of Parallel Import and Export) and was an executive committee member and board member of the Belgian Pharmaceutical Industry Association. He also was a member of the pharmaceutical deontological commission and responsible for this commission in the industry association executive committee.

Marc Foidart

independent director

Marc Foidart obtained a Master in Business Engineering from the University of Liège (1998). He is co-founder of EKLO ASBL.

Marc Foidart obtained a Master in Business Engineering from the University of Liège (1998). He is co-founder of EKLO ASBL, Member of the Executive Committee of Noshaq SA in charge of the Life Sciences sector, CEO of B2H SA, the public company superseding the Liege life sciences ecosystem, and Investment Manager of Epimede SA, a EUR 50 million Belgian based private high-tech growth fund. He has more than 15 years of experience in strategic consulting and investment at all stages of development of small and medium high tech- high growth life sciences enterprises. He played a key role in several financing rounds at critical development stages of various Belgian young biotech companies among which: Mithra Pharmaceuticals SA, Imcyse SA, Uteron Pharma SA, PDC Line Pharma SA, Diagenode SA. As an entrepreneur, Marc Foidart is Co-Founder and past CEO of Arlenda SA, a spin-off company of the University of Liège providing expert statistical solutions to the pharmaceutical, chemical and environment industries. He is also Co-Founder and Executive Chairman of Eyed Pharma SA, a start-up company developing innovative controlled release microimplants in ophthalmology. Marc Foidart has been associate professor at the University of Liege since 2011.

Carolyn Myers

independent director

Dr. Carolyn Myers is an accomplished senior executive with extensive experience creating, growing, and leading health care.

Dr. Carolyn Myers is an accomplished senior executive with extensive experience creating, growing, and leading health care businesses. She is currently Principal of Bioensemble Ltd, a business strategy consulting firm that advises C-suite executives of small and medium size companies on a comprehensive range of drug development, commercial and business development services. Carolyn’s experience comes from having led many businesses in their growth strategies. At Allergan (formerly Actavis), she was the Vice President of Global Business Development and Alliance Management with a focus on expanding product portfolios. At Forest Laboratories (acquired by Actavis), Carolyn was the Vice President of the CNS marketing group responsible for marketing and sales of established and new products. At Mylan she held two different leadership positions including

President of Mylan Technologies, a division focused on developing generic transdermal systems and President of Dey Laboratories having full P&L responsibility to develop, manufacture and sell innovative respiratory products. Carolyn is also an advisor to several start-up organizations and capital investors.

Carolyn earned a PhD in Genetics from the University of British Columbia and an MBA from Rutgers University.

James Gale

independent director

James (Jim) Gale is the founding partner of Signet Healthcare Partners. Jim has over 30 years of healthcare investing and finance experience.

Jim is a Managing Director in Signet Fund IV and is currently the Chairman of the Board of Alpex Pharma S.A., Knight Therapeutics Inc. (TSX: GUD), Teligent (NSDQ: TLGT, formerly IGI Laboratories), and also serves on the Board of Directors of Bionpharma, Chr. Olesen Synthesis A/S, CoreRx, LeonNanodrugs GmbH, Pharmaceutics International (Pii), Advantice Health, and RK Pharma. Prior portfolio company boards include Arbor Pharmaceuticals, Amarin Corporation, eResearch Technologies Inc., and Valera Pharmaceuticals.

Prior to founding Signet, Jim was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, he made a number of investments including Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).

Chris Buyse

Independent Director

Chris Buyse has more than 30 years of international expertise across the healthcare sector.

Chris is currently Managing Director of Fund+, the largest Belgian life sciences-dedicated venture capital fund and serves as member of the board of directors of several European companies listed on Nasdaq and Euronext, including iTeos Therapeutics, Celyad and Inventiva Pharma. Chris is also a Director of the Francqui Foundation, among other private mandates. Chris holds a Master’s Degree in applied economic sciences from the University of Antwerp, and an MBA from the Vlerick School of Management in Ghent.

Stijn Van Rompay

chief executive officer & co-founder

Mr. Stijn Van Rompay has over 20 years of experience in leadership positions at various pharmaceutical companies.

Stijn co-founded and was the CEO of Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.

Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp.

Thomas Jacobsen

chief business development officer & co-founder

Mr. Thomas Jacobsen has over 20 years of experience in the pharmaceutical industry, with expertise in operational management, business development, licensing, and research and development.

He co-founded Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product distribution. Prior to this, he worked with Docpharma, a generics and medical-device company that was acquired by Matrix Laboratories/Mylan Laboratories, where he worked on out-licensing of Docpharma’s products. Thomas started his career in the Scandinavian-based generics company Alternova, where he was responsible for licensing, product registration and launches. Thomas holds a Master’s Degree in Pharmacy from the University of Copenhagen and a Business Degree from Copenhagen Business School.

Jean-Luc Vandebroek

Chief Financial Officer

Jean-Luc Vandebroek is a seasoned executive who joined us in September 2021 from his role as CFO of Bone Therapeutics, a publicly traded biotech company based in Gosselies, Belgium. Prior to that, he was CFO and CIO at Alcopa and Fluxys, and before that, he held various senior financial positions at Delhaize Group. Jean-Luc is an experienced Executive Board member and has a track record of developing and implementing financing strategies and transactions and has a large, global network of investors and financial institutions. Jean-Luc holds a Master in Business Administration from the Louvain Management School.

Dietmar Aichhorn

chief operating officer

Dr. Dietmar Aichhorn, PhD, has over 20 years of experience in various scientific roles within the pharmaceutical industry.

Over the course of his career at Sandoz, Mylan, Innovacell, ViraTherapeutics and Polpharma Biologics, Dietmar has held several senior management positions of increasing responsibilities including Head Clinical Development and Head Development. Dr. Dietmar Aichhorn is an expert in the fields of technical development, clinical development and regulatory affairs in the US, EU and other key geographies. Most recently, Dietmar had an assignment at Polpharma Biologics, where he was responsible for the clinical development of monoclonal antibodies, as well as overseeing all scientific affairs. Dietmar graduated as chemical engineer in Linz but has perfected his project management skills at the university of Vienna.

Koenraad Van der Elst

chief legal officer

Mr. Koenraad Van der Elst has more than 30 years of experience as an in-house and external legal and general counsellor for various listed companies.

Koenraad served as General Counsel at Metris (currently Nikon Metrology), and acted as Secretary General & General Counsel of PUNCH INTERNATIONAL, a Belgian company listed on Euronext Brussels. He was also General Counsel & Secretary to the Board of PUNCH GRAPHIX plc, a company listed on the London Stock Exchange (AIM), and President of the Supervisory Board of PUNCH TECHNIX, a company listed on Euronext Amsterdam. Between 1995 and 2002, Koenraad was the Director of Legal Documentation at the Investment Banking Department (corporate finance & capital markets) of Generale Bank/Fortis Bank and was involved in most capital market transactions in Belgium (take-over bids, exchange offers, initial public offerings, etc.), as well as in a large number of corporate finance deals (M&A, advisory, fairness opinions, mergers, restructurings, etc.), at local, cross-border and international levels.

In addition, Koenraad was an assistant Professor at the University of Brussels (VUB) in Financial Law. He holds a law degree from the University of Brussels (VUB) and an MBA from EHSAL Brussels.

Cookie Policy

Cookie policy

Last updated: November 2nd, 2023

This Cookies Policy explains what Cookies are and how We use them. You should read this policy so You can understand what type of cookies We use, or the information We collect using Cookies and how that information is used.

Cookies do not typically contain any information that personally identifies a user, but personal information that we store about You may be linked to the information stored in and obtained from Cookies.

We do not store sensitive personal information, such as mailing addresses, account passwords, etc. in the Cookies We use.


For the purposes of this Cookie Policy:

  • Company (referred to as either “the Company”, “We”, “Us” or “Our” in this Cookie Policy) refers to Hyloris Pharmaceuticals SA, Boulevard Patience et Beaujonc N°3/1
    4000 Liège.
  • You means the individual accessing or using the Website, or a company, or any legal entity on behalf of which such individual is accessing or using the Website, as applicable.
  • Cookies means small files that are placed on Your computer, mobile device or any other device by a website, containing details of your browsing history on that website among its many uses.
  • Website refers to Hyloris Pharmaceuticals SA, accessible from

Log Files

Log files are maintained and analysed of all requests for files on this website’s web servers. Log files capture personal information in the form of the user’s IP address as well as the browser type/version, operating system used, URL of the previously visited page and the time of the server request.

Aggregated analysis of these log files is used to monitor website usage. The legal basis for this analysis are our legitimate interests for enhancing your experience on our Website. These analyses may be made available to Hyloris Pharmaceuticals staff and partner agencies to allow them to measure, for example, overall popularity of the site and typical user paths through the site.

Hyloris Pharmaceuticals will make no attempt to track or identify individual users via the log file data, except where there is a reasonable suspicion that unauthorised access to systems is being attempted. In the case of all users, Hyloris Pharmaceuticals reserves the right to attempt to identify and track any individual who is reasonably suspected of trying to gain unauthorised access to computer systems or resources operating as part of Hyloris Pharmaceuticals web services.

All log file information collected by Hyloris Pharmaceuticals is kept secure and no access to raw log files is given to any third party.


This Website uses ‘cookies’. Cookies are small text files which are placed on your hard drive in order to facilitate the use of our Website. These text files help to identify you when you return to our Website. Some cookies are used to store preferences and are deleted after the end of the browser session, i.e. after closing the browser (so-called session cookies). Other cookies serve to better adjust the Website to user needs and remain on the end device (so-called permanent or persistent cookies). In the following, we explain which cookies we use.

HYLORIS PHARMACEUTICALS uses cookies which are necessary for the website to function. The legal basis for these cookies are our legitimate interests that our Website is displayed correctly.

Further, we use performance, functional and targeting cookies for statistics and analysis concerning the use of the Website. The legal basis for the use of these cookies is your consent. You can consent to activate all cookies by clicking the button “Accept Cookies” in our cookie banner or activate the cookie categories separately under “Cookie Settings”.

Any cookies that may be used by this Website are used solely on a per session basis.

Cookie Name Description Duration
Strictly necessary cookies
76d1e5a58d5f09f23b17abf8168c6bfc, FirstVisit These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work session cookie
Performance Cookies
(provided by Google Analytics)
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. session cookie
Functional Cookies
OptanonConsent, OptanonAlertBoxClosed
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly. session cookie
Targeting Cookies
(set by third parties)
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising. session cookie

Google Analytics

Google Analytics is a web analysis service of Google LLC. (, 1600 Amphitheatre Parkway, Mountain View, CA 94043, USA (“Google”). The information generated by the cookie about your use of this website (e.g. browser type/version, operating system used, URL of the previously visited page, IP address, time of server request) are transmitted to a Google server in the USA and stored there. The user profiles are created in pseudonymised form.

The information obtained enables us to evaluate the use of our website and to record user activities. Google also provides other services related to the use of the website and the Internet in order to conduct market research and to be able to design our website in order to better correspond to user´s interests. The information may be passed on to third parties if this is required by law or if third parties process this data on behalf of the company. Your IP address will be anonymized (IP masking) and in no case merged with other Google data.

You can prevent this processing by Google and the collection of your data relating to the use of the website (including your IP address) by downloading and installing a browser add-on ( This link also provides further information on deactivating and installing the browser add-on.

For more information about Google Analytics’ privacy practices, please visit

How to enable and disable cookies using your browser

Google Chrome

  • Click the wrench icon on the browser toolbar
  • Select Settings
  • Click ‘Show advanced settings’
  • In the “Privacy” section, click the ‘Content settings’ button
  • To enable cookies in the “Cookies” section, pick ‘Allow local data to be set’, this will enable both first-party and third-party cookies. To allow only first-party cookies pick ‘Block all third-party cookies without exception’
  • To disable cookies, in the “Cookies” section, pick ‘Block sites from setting any data’
  • Note there are various levels of cookie enablement and disablement in Chrome. For more information on other cookie settings offered in Chrome, refer to the following page from Google:

Microsoft Internet Explorer 6.0, 7.0, 8.0, 9.0

  • Click on ‘Tools’ at the top of your browser window and select ‘Internet Options’
  • In the options window navigate to the ‘Privacy’ tab
  • To enable cookies: Set the slider to ‘Medium’ or below
  • To disable cookies: Move the slider to the top to block all cookies
  • Note there are various levels of cookie enablement and disablement in Explorer. For more information on other cookie settings offered in Internet Explorer, refer to the following page from Microsoft:

Mozilla Firefox

  • Click on ‘Tools’ at the browser menu and select ‘Options’
  • Select the Privacy panel
  • To enable cookies: Check ‘Accept cookies for sites’
  • To disable cookies: Uncheck ‘Accept cookies for sites’
  • Note there are various levels of cookie enablement and disablement in Firefox. For more information, refer to the following page from Mozilla: and disabling cookies


  • Click on ‘Setting’ at the browser menu and select ‘Settings’
  • Select ‘Quick Preferences’
  • To enable cookies: check “Enable Cookies”
  • To disable cookies: uncheck “Enable Cookies”
  • Note there are various levels of cookie enablement and disablement in Opera. For more information on other cookie settings offered in Opera, refer to the following page from Opera Software:

Safari on OSX

  • Click on ‘Safari’ at the menu bar and select the ‘Preferences’ option
  • Click on ‘Security’
  • To enable cookies: In the ‘Accept cookies’ section select ‘Only from site you navigate to’
  • To disable cookies: In the ‘Accept cookies’ section select ‘Never’
  • Note there are various levels of cookie enablement and disablement in Safari. For more information on other cookie settings offered in Safari, refer to the following page from Apple:

All other browsers

  • Please look for a “help” function in the browser or contact the browser provider.

More Information about Cookies

You can learn more about Cookies at the following third-party websites:

  • Network Advertising Initiative:

Contact Us

If you have any questions about this Cookies Policy, You can contact us:

  • By email:
  • By visiting this page on our website:
  • By phone number: +32 (0)4 346 02 07